The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cann Group (CAN) may have lost around $3.6 million in a recent cyber security breach
  • On Febuary 4, payments made by Cann to an overseas contractor were received by an unknown third party
  • Cann has been working with its bank to determine if any payments can be halted or recovered
  • The incident is being investigated thoroughly by Cann and its overseas contractor, with the help of external security and forensic IT experts
  • The company says operations and projects will continue, irrespective of the money being recovered
  • Cann is in the grey, with shares trading at 66 cents

Cann Group (CAN) may have lost around $3.6 million in a recent cyber security breach.

On February 4, Cann Group made payments of around $3.6 million to an overseas contractor for works being undertaken at its Milura factory.

Overnight, however, the funds were intercepted by an unknown third party in a complex cyber fraud effort.

Acting quickly, Cann began working with its bank to determine if any of the payments could be halted or recovered. Insurance brokers were also immediately notified to determine if a claim can be made to recover any of the losses involved.

Meanwhile, Cann is also working to weed out any issues towards the integrity of its IT systems.

The company says despite the loss it is able to continue to grow its operations and projects, including the construction of its Mildura facility, regardless of any funds being recovered.

The incident is now being investigated thoroughly by both Cann and its overseas contractor, with the help of external security and forensic IT experts.

The matter has been reported to police in Victoria, plus the Netherlands and Hong Kong, as well as the Office of Drug Control.

Cann is in the grey, last trading at 66 cents at 10:12 am AEDT.

CAN by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…